Holen Sie sich die Stockscreener-App
0.6746
2.02%
-0.0138
Schlusskurs vom Vortag:
$0.6884
Offen:
$0.72
24-Stunden-Volumen:
142.42K
Relative Volume:
1.01
Marktkapitalisierung:
$90.83M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-70.78M
KGV:
-1.2046
EPS:
-0.56
Netto-Cashflow:
$-61.27M
1W Leistung:
-6.32%
1M Leistung:
-24.00%
6M Leistung:
-76.00%
1J Leistung:
-72.91%
1-Tages-Spanne:
$0.67
$0.72
1-Wochen-Bereich:
$0.665
$0.8222
52-Wochen-Spanne:
$0.66
$3.09
Nautilus Biotechnology Inc Stock (NAUT) Company Profile
Firmenname
Nautilus Biotechnology Inc
Sektor
Branche
Telefon
206-333-2001
Adresse
2701 EASTLAKE AVE EAST, SEATTLE
Vergleichen Sie NAUT mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
NAUT
Nautilus Biotechnology Inc
|
0.6746 | 90.83M | 0 | -70.78M | -61.27M | -0.56 |
|
VRTX
Vertex Pharmaceuticals Inc
|
493.63 | 122.76B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
606.78 | 61.38B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
614.03 | 36.37B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
253.60 | 30.12B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
250.19 | 24.70B | 3.81B | -644.79M | -669.77M | -6.24 |
Nautilus Biotechnology Inc Stock (NAUT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-12-05 | Herabstufung | Goldman | Neutral → Sell |
| 2024-06-27 | Eingeleitet | Guggenheim | Buy |
| 2024-06-03 | Fortgesetzt | Jefferies | Hold |
| 2022-01-06 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2021-11-02 | Eingeleitet | Cowen | Outperform |
| 2021-08-04 | Eingeleitet | Goldman | Neutral |
| 2021-07-13 | Eingeleitet | Jefferies | Buy |
Alle ansehen
Nautilus Biotechnology Inc Aktie (NAUT) Neueste Nachrichten
Nautilus Biotechnology (NAUT) Expected to Announce Quarterly Earnings on Tuesday - American Banking and Market News
Nautilus Biotechnology (NAUT) to Release Earnings on Tuesday - Defense World
Nautilus Biotechnology Inc expected to post a loss of 15 cents a shareEarnings Preview - TradingView
Short Interest in Nautilus Biotechnology, Inc. (NASDAQ:NAUT) Increases By 20.5% - Defense World
Nautilus Biotechnology to Announce First Quarter 2025 Financial Results on April 29, 2025 - The Manila Times
Nautilus Biotechnology Appoints Mass Spectrometry Leader Ken Suzuki as Chief Marketing Officer - MarketScreener
NAUT Stock Plummets to 52-Week Low at $0.82 Amid Market Turbulence By Investing.com - Investing.com South Africa
NAUT Stock Plummets to 52-Week Low at $0.82 Amid Market Turbulence - Investing.com India
Nautilus Biotechnology, Inc. (NASDAQ:NAUT) Stock Position Decreased by Charles Schwab Investment Management Inc. - Defense World
Virtu Financial LLC Takes $28,000 Position in Nautilus Biotechnology, Inc. (NASDAQ:NAUT) - Defense World
Virtu Financial LLC Takes $30,000 Position in FlexShopper, Inc. (NASDAQ:FPAY) - Defense World
We're Keeping An Eye On Nautilus Biotechnology's (NASDAQ:NAUT) Cash Burn Rate - Yahoo Finance
Nautilus Biotechnology: Hold Rating Amid Delayed Launch and Strategic Adjustments - TipRanks
Nautilus Biotechnology’s Earnings Call: Progress Amid Challenges - TipRanks
Nautilus Biotechnology, Inc. (NASDAQ:NAUT) Q4 2024 Earnings Call Transcript - Insider Monkey
Nautilus Biotechnology lays off 16% of workforce, plans release of commercial platform in 2026 - MSN
Nautilus: Trading Below An Albeit Lower Net Cash Figure (NASDAQ:NAUT) - Seeking Alpha
Guggenheim cuts Nautilus Biotech target to $2.50, keeps buy rating - Investing.com
Guggenheim cuts Nautilus Biotech target to $2.50, keeps buy rating By Investing.com - Investing.com South Africa
Nautilus Biotechnology Reports 2024 Financial Results - TipRanks
Seattle's Nautilus Biotechnology lays off 16% of its staff - The Business Journals
Nautilus Biotechnology Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Earnings call transcript: Nautilus Q4 2024 highlights platform delay - Investing.com
Nautilus Biotechnology, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2024 - Marketscreener.com
Nautilus Biotechnology Reports Fourth Quarter and Fiscal Year 2024 Financial Results - The Manila Times
Nautilus Cuts 16% of Workforce as Biotech Platform Launch Slips to 2026What's Next? - StockTitan
Nautilus Biotechnology Announces Board Changes for 2025 - TipRanks
Nautilus Biotechnology (NAUT) Projected to Post Quarterly Earnings on Thursday - MarketBeat
Blade Air Mobility Leads The Charge Among 3 US Penny Stocks - Simply Wall St
Nautilus Biotechnology to Participate in the TD Cowen 45th Annual Healthcare Conference - The Manila Times
Exclusive: Nautilus Biotech Unveils Next-Gen Protein Analysis Breakthrough at Major Healthcare Summit - StockTitan
Nautilus Biotechnology, Inc. (NASDAQ:NAUT) Short Interest Down 68.8% in January - MarketBeat
Nautilus Biotechnology (NASDAQ:NAUT) Stock Price Down 5.9%Time to Sell? - MarketBeat
SG Americas Securities LLC Buys 9,904 Shares of Nautilus Biotechnology, Inc. (NASDAQ:NAUT) - Defense World
NAUTNautilus Biotechnology Inc Latest Stock News & Market Updates - StockTitan
Nautilus Bio Q4 Earnings Alert: Protein Analysis Pioneer Reports Feb 27 - StockTitan
Nautilus Biotechnology to Announce Fourth Quarter and Full Year 2024 Financial Results on February 27, 2025 - GlobeNewswire
One Nautilus Biotechnology Insider Raised Their Stake In The Previous Year - Yahoo Canada Finance
Nautilus Biotech announces board member changes By Investing.com - Investing.com Australia
Nautilus Biotech announces board member changes - MSN
Nautilus Biotechnology Announces Board Member Departures - MSN
NAUTILUS BIOTECHNOLOGY, INC. : Results of Operations and Financial Condition, Financial Statements and Exhibits (form 8-K) - Marketscreener.com
Barclays PLC Buys 47,059 Shares of Nautilus Biotechnology, Inc. (NASDAQ:NAUT) - Defense World
Jeff Bezos Stock Portfolio: Top Investment Picks - CoinCodex
Nautilus Biotechnology, Inc. (NASDAQ:NAUT) Short Interest Down 14.2% in December - MarketBeat
Finanzdaten der Nautilus Biotechnology Inc-Aktie (NAUT)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.63%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):